Predictmedix AI Expands Diagnostic Reach in India with Innovative Diabetes Non-Invasive Screening

Toronto, Ontario – August 21, 2023– Predictmedix AI Inc. (CSE: PMED) (OTCQB: PMEDF) (FRA:3QP) (the "Company" or "Predictmedix") today announced a recent technological milestone in its AI product suite – the ability to detect early signs of diabetes in individuals by analyzing subtle biological indicators, often undetected by conventional methods. Predictmedix AI's expansion into diabetic screening seamlessly aligns with its mission in providing cutting-edge, personalized healthcare solutions worldwide.

Anticipating India's Rising Diabetes Concerns, Predictmedix AI has developed the non-invasive ability of early detection of the disease. The company, a pioneering force in artificial intelligence-driven diagnostics on a global scale, is excited to introduce its diabetes screening solution to its comprehensive lineup of AI-powered healthcare offerings. As India faces an escalating diabetes challenge, Predictmedix AI's new initiative aims to transform current modalities for early detection and intervention for this prevalent chronic ailment. India, a country grappling with a significant diabetes burden, has witnessed an alarming surge in diabetes cases in recent years.

According to a study by the Indian Council of Medical Research (ICMR) conducted in 2021, India had an estimated 101 million people with diabetes and 136 million individuals with pre-diabetes.[1] Instances of diabetes, pre-diabetes, and hypertension have been on the rise in the Asian subcontinent, highlighting the urgency of the situation.

Recognizing the critical need to address this growing health crisis, Predictmedix AI's latest addition to its technology suite holds the promise of ushering in a transformative impact on public health. The company's newly introduced diabetes non-invasive screening solution harnesses the power of advanced AI algorithms to analyze a wide spectrum of pertinent data, encompassing blood flow patterns to monitor volumetric variation in blood circulation which changes with varying blood sugar levels. Through the identification of subtle indicators, often undetectable by conventional methods, Predictmedix AI's technology demonstrates precision in identifying early signs of diabetes. Timely detection holds paramount importance, enabling healthcare professionals to initiate prompt interventions, empowering patients to effectively manage their condition and potentially sidestep severe complications.

Diabetes is a global health challenge, particularly evident in India," remarked Rahul Kushwah, Chief Operating Officer of Predictmedix AI. "Our commitment to enhancing healthcare outcomes through innovative technology has led us to develop this diabetic screening solution. By harnessing the capabilities of AI to pinpoint potential cases at an early juncture, our aim is to significantly contribute to individual well-being and the larger community."

The significance of early diabetic screening cannot be emphasized enough. Timely

detection empowers individuals to make well-informed decisions regarding their health, adopt healthier lifestyles, and gain access to appropriate medical interventions. Furthermore, it alleviates the burden on healthcare systems by mitigating the progression of diabetes-linked complications, such as cardiovascular disorders, kidney afflictions, and nerve   impairment.

The global market for Diabetes Diagnostics, estimated at US$30.8 Billion in 2022, is projected to attain a revised size of US$59.4 Billion by 2030, reflecting a compound annual growth rate (CAGR) of 8.6% over the analysis period of 2022-2030.[2]

[1]https://www.livemint.com/science/health/diabetes-epidemic-experts-sound-alarm-as-study-shows-over-11-indians-are-diabetic-goa-records-highest-number-11686315817278.html

[2]https://finance.yahoo.com/news/global-diabetes-diagnostics-business-report-171500487.html

About Predictmedix AI Inc.

Predictmedix AI Inc. (CSE: PMED) (OTCQB: PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations – powered by a proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including infectious diseases such as COVID-19, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedi AI's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn.

Public Relations Contact

For further media information or to set up an interview, please contact:

Nelson Hudes Hudes

Communications International (905) 660 9155

Nelson@hudescommunications.com

Dr. Rahul Kushwah (647) 889 6916

Caution Regarding Forward-Looking Information:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.